ライフサイエンスコーパス: active pulmonary tuberculosis

1 ogressive phenotypes of latent infection and active pulmonary tuberculosis.

2 nchoalveolar lavage cells from patients with active pulmonary tuberculosis.

3 vation occur at extrapulmonary sites without active pulmonary tuberculosis.

4 t M. tuberculosis infection will progress to active pulmonary tuberculosis.

5 point-of-care assay as a screening tool for active pulmonary tuberculosis.

6 ncreased in BAL cells from involved sites of active pulmonary tuberculosis.

7 lavage from involved sites in patients with active pulmonary tuberculosis.

8 ion was made of not isolating a patient with active pulmonary tuberculosis.

9 pted to analyze these cells in patients with active pulmonary tuberculosis.

10 CH1 expression is associated clinically with active pulmonary tuberculosis.

11 er respiratory tract sampling for diagnosing active pulmonary tuberculosis.

12 Of 354 patients with active pulmonary tuberculosis, 274 successfully complete

13 rium tuberculosis in plasma of patients with active pulmonary tuberculosis, a disease that urgently n

14 s a major risk factor for the development of active pulmonary tuberculosis, although the immunologica

15 e cohort study of HIV-infected patients with active pulmonary tuberculosis and baseline CD4 counts </

16 pha in bronchoalveolar lavage (BAL) cells in active pulmonary tuberculosis, and evaluated the mechani

17 y household contacts (HHCs) of patients with active pulmonary tuberculosis are exposed aerogenically

18 B) generated from the cough of patients with active pulmonary tuberculosis are the source of MTB infe

19 el of human plasma proteins in patients with active pulmonary tuberculosis (ATB) throughout anti-TB t

20 A substantial proportion of active pulmonary tuberculosis cases in countries where t

21 luate the efficacy of M72/AS01(E) to prevent active pulmonary tuberculosis disease according to the f

22 ) efficacy in a phase 2B trial in preventing active pulmonary tuberculosis disease, but potential cos

23 he vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident s

24 horts were household contacts of adults with active pulmonary tuberculosis disease.

25 In contrast, the cellular immune response in active pulmonary tuberculosis disrupts this innate immun

26 patients with primary and secondary cases of active pulmonary tuberculosis from the southern region (

27 e cohort of reported patients with suspected active pulmonary tuberculosis in 2008-2010 from Georgia,

28 Placing inpatients with presumed active pulmonary tuberculosis in respiratory isolation p

29 A composite reference standard for active pulmonary tuberculosis incorporated chest radiogr

30 d datasets that examined clinical cohorts of active pulmonary tuberculosis infection in whole blood.

31 patitis C, human immunodeficiency virus, and active pulmonary tuberculosis is considered.

32 Active pulmonary tuberculosis is difficult to diagnose a

33 Eight participants with active pulmonary tuberculosis (mean age, 48.1 years; age

34 ng all culture-positive patients treated for active pulmonary tuberculosis (n = 372) in San Francisco

35 mononuclear cells (PBMC) from patients with active pulmonary tuberculosis (n=16) and healthy subject

36 SPOT.TB (T-SPOT) among adults with suspected active pulmonary tuberculosis or patients with confirmed

37 We determined TL and mtDNA content among active pulmonary tuberculosis (PTB) patients to assess i

38 In active pulmonary tuberculosis (PTB), the ratio of cortis

39 ammadelta T cells of patients diagnosed with active pulmonary tuberculosis showed that compared with

40 All active pulmonary tuberculosis (TB) cases newly diagnosed

41 ever, detection of anti-CCP in patients with active pulmonary tuberculosis (TB) has recently been rep

42 hroughout the United States for all cases of active pulmonary tuberculosis (TB) to identify secondary

43 as screen to initiate diagnostic testing for active pulmonary tuberculosis (TB), yet the performance

44 Active pulmonary tuberculosis was diagnosed in the Unite

45 a 6-month rifampicin-containing regimen for active pulmonary tuberculosis, were randomly assigned 1